Newamsterdam Pharma Company N V (NAMSW)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile

Newamsterdam Pharma Company N V

Healthcare (1195)

Biotechnology (680)

31 35 206 2971

Gooimeer 2-35, Naarden

Nächster Verdiensttermin

Neueste SEC-Einreichungen

NAMSW's Discussions on Twitter

Newamsterdam Pharma Company N V Aktie (NAMSW) Neueste Nachrichten

Finanzdaten der Newamsterdam Pharma Company N V-Aktie (NAMSW)

Es liegen keine Finanzdaten für Newamsterdam Pharma Company N V (NAMSW) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Newamsterdam Pharma Company N V (NAMSW)

Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile

Newamsterdam Pharma Company N V Aktie (NAMSW) Neueste Nachrichten

(NAMS) Technical Pivots with Risk Controls - Stock Traders Daily

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November - 24matins.uk

Needham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN

NewAmsterdam Pharma to Restate Prior Financials By Investing.com - Investing.com Australia

NewAmsterdam Pharma to Restate Prior Financials - Investing.com India

(NAMSW) Trading Report - Stock Traders Daily

NewAmsterdam Pharma Breaks Above 200-Day Moving AverageBullish for NAMS - Nasdaq

Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $33.80 - MarketBeat

NewAmsterdam Pharma Company N.V. (NAMS) Price Target Increased by 8.93% to 31.11 - MSN

Marshall Wace LLP Decreases Stake in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

When the Price of (NAMSW) Talks, People Listen - Stock Traders Daily

Millennium Management LLC Has $22.39 Million Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies - Seeking Alpha

NewAmsterdam Pharma executive sells shares worth $707,400 By Investing.com - Investing.com South Africa

NewAmsterdam Pharma executive sells shares worth $707,400 - Investing.com India

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down to $16.60 - MarketBeat

NewAmsterdam Pharma Company NV (NAMS) rating initates by TD Cowen - Knox Daily

Does NewAmsterdam Pharma Company NV (NAMS) offer a good opportunity for investors? - SETE News

Newamsterdam Pharma exec buys $17,332 in company stock By Investing.com - Investing.com Australia

Newamsterdam Pharma exec buys $17,332 in company stock - Investing.com India

NewAmsterdam Pharma (NASDAQ:NAMS) Sees Strong Trading Volume - MarketBeat

TD Cowen Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN

Deerfield Management Company L.P. Series C Has $16.70 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Affinity Asset Advisors LLC Boosts Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Investment opportunity in NewAmsterdam Pharma stock as anticipation builds for BROADWAY results By Investing.com - Investing.com

NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Overweight" Rating from Piper Sandler - MarketBeat

Expert Ratings For NewAmsterdam Pharma - Benzinga

Piper sees ‘attractive buying opportunity’ into NewAmsterdam data - TipRanks

NWF Group Shareholding Structure Altered - TipRanks

'She's A Hardy Filly': Ocean Club Goes All The Way On Front End In Noble Damsel - Paulick Report

Ocean Club Skims to Narrow Victory in Noble Damsel - BloodHorse.com

Ocean Club, in quick turnaround, holds off Five Towns, Breath Away to take Noble Damsel - Daily Racing Form

Trend Tracker for (NAMS) - Stock Traders Daily

Top Bud padlocked in Holland Patent for illegal cannabis - Rome Sentinel

Kenneth Law, who sold poisonous chemical linked to 131 deaths, sued by Ontario teen's parents - CBC.ca

NewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

While institutions own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), private equity firms are its largest shareholders with 47% ownership - Yahoo Finance

NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Outperform" Rating from Royal Bank of Canada - MarketBeat

NewAmsterdam Pharma (NASDAQ:NAMS) Short Interest Up 20.7% in August - MarketBeat

NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan

Buying Buzz: NewAmsterdam Pharma Company NV [NAMS] Chief Executive Officer Davidson Michael H. purchases 5,000 shares of the company – Knox Daily - Knox Daily

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September - Yahoo Finance

NewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading Volume - MarketBeat

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside - Benzinga

NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Analysts at Needham & Company LLC - MarketBeat

NewAmsterdam shares hold Buy rating on strong trial data - Investing.com

NewAmsterdam Pharma Company NV (NAMS)’s Market Momentum: Closing Strong at 16.76, Up 3.08 - The Dwinnex

You might want to take a look at NewAmsterdam Pharma Company NV (NAMS) now - SETE News

The Future of NewAmsterdam Pharma Company NV: Analyzing NAMS - The InvestChronicle

NewAmsterdam Pharma Company NV [NAMS] is 47.99% higher this YTD. Is it still time to buy? - The DBT News

Finanzdaten der Newamsterdam Pharma Company N V-Aktie (NAMSW)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie NAMSW